Bio-Techne
TECH
$46.70
+2.71%
Bio-Techne Corp. is a life sciences manufacturer supplying essential consumables and instruments, such as reagents, antibodies, and analytical tools, to the pharmaceutical, biotechnology, academic, and diagnostic markets. The company operates as a specialized supplier with a diversified portfolio split between its Protein Sciences segment (approximately 75% of revenue) and its Diagnostics and Genomics segment (25%). The current investor narrative is dominated by concerns over a significant slowdown in growth, as evidenced by a recent quarterly revenue decline and a sharp, sustained drop in the stock price, which has underperformed the broader market dramatically. Recent news highlights a bifurcated market driven by AI hype, placing Bio-Techne's traditional life sciences tools business in stark contrast to high-growth sectors, raising questions about its near-term demand environment and competitive positioning.…
TECH
Bio-Techne
$46.70
Investment Opinion: Should I buy TECH Today?
Rating: Hold. The core thesis is that while the stock is deeply oversold and priced for a significant earnings recovery, the fundamental deterioration in revenue growth creates too much near-term uncertainty to warrant a Buy rating, especially given the lack of clear analyst price targets for upside calculation.
Supporting evidence includes the stark contrast between a trailing P/E of 110.4x and a forward P/E of 21.0x, which hinges entirely on achieving the analyst consensus EPS of $3.15. Revenue growth has stalled at -0.39% YoY, but the company maintains strong gross margins of 64.65% and a robust balance sheet with a current ratio of 3.46. The stock's technical position, trading just 0.2% above its 52-week low after a -27% six-month decline, suggests much bad news is priced in.
The thesis would upgrade to a Buy if quarterly revenue returns to positive growth and the company demonstrates progress toward the $3.15 EPS target, providing validation for the forward multiple. It would downgrade to a Sell if revenue declines accelerate or if margins compress significantly, breaking the 52-week low support and signaling the downtrend has further to run. Relative to its own history and sector peers, the stock appears fairly valued for the high risk it currently embodies, trading at a premium PS ratio that demands a growth resurgence to justify.
Sign up to view all
TECH 12-Month Price Forecast
The investment case for TECH is balanced on a knife's edge between a compelling valuation reset and a fundamental growth scare. The forward P/E suggests the market is pricing in a successful turnaround, but the recent revenue decline provides little evidence to support that optimism. The neutral stance reflects this high uncertainty; the strong balance sheet and oversold condition limit near-term downside, but the lack of a visible growth catalyst prevents bullish conviction. The stance would turn bullish on confirmation of revenue reacceleration and margin stability in the next earnings report. It would turn bearish if the stock breaks below $43 support on high volume, signaling the downtrend has further to go.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bio-Techne's 12-month outlook, with a consensus price target around $60.71 and implied upside of +30.0% versus the current price.
Average Target
$60.71
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$37 - $61
Analyst target range
Analyst coverage for TECH is limited, with only three firms providing estimates, indicating this is a mid-cap stock with less institutional scrutiny which can lead to higher volatility. The consensus sentiment appears cautiously optimistic on fundamentals, with an average EPS estimate of $3.15 and revenue estimate of $1.71 billion for the upcoming period, but no explicit price targets or buy/hold/sell distribution is provided in the data, making a precise upside calculation impossible. The available institutional ratings from early 2026 show a mix of opinions, including 'Buy' ratings from Citigroup and UBS and 'Hold' from Stifel, but the lack of a published target price range and the minimal number of analysts signal high uncertainty and a wide dispersion of potential outcomes. This limited coverage environment means price discovery is less efficient, and the stock's recent severe underperformance may not be fully reflected in analyst models, leaving investors with fewer established benchmarks for valuation.
Bulls vs Bears: TECH Investment Factors
The evidence currently favors the bear case, driven by the concrete deterioration in revenue growth, sustained negative momentum, and a valuation that remains elevated despite the sharp price decline. The most critical tension in the investment debate is whether the company's current financial strength and expected earnings recovery (forward P/E of 21x) can overcome the clear and present danger of a fundamental growth stall. The resolution hinges on the next few quarters of revenue performance; if growth returns, the stock is deeply oversold, but if stagnation persists, further multiple compression is likely.
Bullish
- Strong Balance Sheet & Financial Flexibility: The company maintains a robust current ratio of 3.46 and a low debt-to-equity ratio of 0.23, providing significant cushion to weather the current downturn. This financial strength reduces near-term solvency risk and supports strategic flexibility.
- Analysts Expect Significant Earnings Recovery: The forward P/E of 21.0x is a dramatic discount to the trailing P/E of 110.4x, implying the market expects a substantial earnings rebound. Analyst consensus projects FY EPS of $3.15, which would represent a massive recovery from the TTM diluted EPS of $0.009.
- Stock Deeply Oversold Near 52-Week Low: Trading at $43.30, the stock is just above its 52-week low of $43.195, having fallen 27.08% over the past six months and 25.97% in the past month. This extreme technical oversold condition suggests a large portion of negative sentiment may already be priced in.
- Healthy Gross Margins and Free Cash Flow: The company reported a quarterly gross margin of 64.65% and generates substantial free cash flow, with TTM FCF of $223 million. This operational profitability provides a foundation for recovery even as revenue growth stalls.
Bearish
- Revenue Growth Has Stalled and Turned Negative: Most recent quarterly revenue of $295.9 million declined -0.39% year-over-year, a stark reversal from prior growth. This indicates underlying demand weakness in its core Protein Sciences segment, which drives 75% of sales.
- Extreme Valuation Compression Risk Remains: Despite the sharp decline, the stock still trades at a premium Price/Sales ratio of 6.64 and a trailing P/E of 110.4x. If growth fails to reaccelerate, these multiples are vulnerable to further compression towards sector averages.
- Severe Underperformance & High Volatility: The stock has a beta of 1.405 and has underperformed the SPY by -31.57% over the past month, with a max drawdown of -39.33%. This high volatility and negative momentum create a challenging environment for investor confidence.
- Limited Analyst Coverage & High Uncertainty: Only three analysts provide coverage, and no explicit price targets are given, indicating low institutional scrutiny and high uncertainty. This lack of consensus makes price discovery less efficient and increases volatility risk.
TECH Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -10.24% and a 6-month decline of -27.08%. As of the latest close at $43.30, the price is trading near the bottom of its 52-week range, at just 40% of the span between its 52-week low of $43.195 and high of $72.16, indicating the stock is deeply oversold and approaching its yearly low. Recent momentum has been severely negative, with the stock down -25.97% over the past month and -27.75% over the past three months, a stark underperformance compared to the SPY's gains of +5.6% and +8.42% over the same periods, signaling accelerating selling pressure. Key technical support is clearly defined at the 52-week low of $43.195, while resistance sits at the 52-week high of $72.16; a decisive break below support could trigger further capitulation, while a recovery would need to overcome significant overhead supply. The stock's beta of 1.405 indicates it is 40.5% more volatile than the market, which, combined with a max drawdown of -39.33%, underscores its high-risk profile during this downturn.
Beta
1.41
1.41x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$43-$72
Price range past year
Annual Return
-5.7%
Cumulative gain past year
| Period | TECH Return | S&P 500 |
|---|---|---|
| 1m | -22.9% | +4.6% |
| 3m | -19.8% | +8.3% |
| 6m | -24.1% | +12.5% |
| 1y | -5.7% | +25.0% |
| ytd | -21.7% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TECH Fundamental Analysis
Revenue growth has stalled, with the most recent quarterly revenue of $295.9 million representing a slight year-over-year decline of -0.39%, a concerning shift from the growth trajectory seen in prior comparable periods. The company's two primary segments show that consumables, at $235.4 million, remain the dominant revenue driver, but the overall flat performance suggests underlying demand weakness. Profitability metrics are mixed; the company reported net income of $38.0 million for the quarter with a gross margin of 64.65%, but the trailing twelve-month diluted EPS is a mere $0.009, indicating significant earnings volatility and potential compression when viewed on an annualized basis. Operating margin for the quarter was 18.41%, but the forward-looking net margin of 6.02% suggests expectations of profitability pressure ahead. The balance sheet remains relatively healthy with a strong current ratio of 3.46 and a modest debt-to-equity ratio of 0.23, providing financial flexibility. However, the free cash flow yield, implied by a TTM free cash flow of $223.0 million against an $8.1 billion market cap, is approximately 2.75%, which is modest, and an ROE of 3.83% indicates subpar returns on shareholder equity in the recent period.
Quarterly Revenue
$295877000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$223020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TECH Overvalued?
Given the company's positive but minimal trailing net income, the primary valuation metric selected is the trailing P/E ratio, which stands at an elevated 110.4x. The forward P/E of 21.0x presents a dramatic discount, implying the market expects a significant earnings recovery in the coming year, though this forward multiple is still rich relative to historical norms. Compared to sector averages, the stock trades at a substantial premium on a Price/Sales basis, with a PS ratio of 6.64, which is typically high for a life sciences tools company, suggesting the market has historically priced in strong growth and margins that are now being questioned. Historically, the stock's own valuation has contracted sharply from its peaks; for instance, its P/E ratio has fallen from over 292x in mid-2021 to the current 110x, yet it remains well above the lower end of its historical range seen in recent years, indicating the multiple compression may not be complete if growth fears persist.
PE
110.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -113x~293x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
38.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's stalled growth trajectory and profitability pressures. The recent quarterly revenue decline of -0.39% YoY signals demand weakness, particularly concerning for a business where 75% of revenue comes from the Protein Sciences segment. While gross margins remain healthy at ~65%, the forward net margin of 6.02% suggests expectations of profit compression, and the TTM diluted EPS of $0.009 indicates significant earnings volatility. The modest free cash flow yield of ~2.75% offers limited cushion if operational performance deteriorates further.
Market & Competitive Risks are heightened by the stock's premium valuation and sector headwinds. Trading at a PS ratio of 6.64, TECH commands a premium multiple that is vulnerable if the market continues to favor high-growth AI sectors over traditional life sciences tools, as highlighted in recent news. The beta of 1.405 indicates the stock is 40.5% more volatile than the market, amplifying downside during sector rotations or broad market pullbacks. Competitive pressures and potential budget constraints in academic and biotech research funding pose external threats to top-line recovery.
Worst-Case Scenario involves a continuation of the current downtrend where revenue fails to reaccelerate and margin pressure intensifies, leading to consecutive earnings misses. This could trigger a loss of investor confidence, analyst downgrades, and a derating of the valuation multiple towards its historical lows. The realistic downside could see the stock break its 52-week low support of $43.195 and retreat towards levels implied by a more distressed scenario, potentially resulting in a total drawdown from the current price exceeding -40%, aligning with the stock's recent max drawdown of -39.33%.
FAQ
The primary risk is fundamental: a prolonged slowdown in revenue growth, as evidenced by the -0.39% YoY decline last quarter, which could lead to further earnings misses and valuation multiple compression. Competitive and market risks are significant, as the company operates in a sector currently out of favor compared to AI, and its high beta of 1.405 means it will fall more than the market in a downturn. Financial/model risk is also high due to limited analyst coverage (only 3 firms), which reduces visibility and consensus, increasing volatility. Finally, technical risk is elevated with the stock testing its 52-week low; a break below could trigger accelerated selling.
The 12-month outlook for TECH is highly uncertain, with three distinct scenarios. The base case (50% probability) sees the stock trading between $50 and $58 as revenue stabilizes and a partial earnings recovery occurs. The bull case (25% probability) could see a rally to $65-$72 if growth reaccelerates and sentiment improves. The bear case (25% probability) warns of a drop to $38-$43 if the downturn worsens. The most likely outcome is the base case, which assumes the company muddles through with flat growth but manages costs to deliver improved, though not stellar, profitability.
TECH's valuation is schizophrenic and entirely dependent on the time frame. On a trailing basis, it appears extremely overvalued with a P/E of 110.4x, justified only by depressed recent earnings. On a forward basis, it appears more reasonably valued at a P/E of 21.0x, but this hinges on achieving a massive EPS recovery to $3.15. Its Price/Sales ratio of 6.64 is at a premium, suggesting the market still prices in strong future growth and margins. Overall, the stock is fairly valued for the significant uncertainty it embodies; it is not cheap enough to be a clear value play nor expensive enough to be a clear short if growth returns.
TECH presents a high-risk, high-potential-reward situation that is not suitable for all investors. For a speculative investor with a long-term horizon and tolerance for volatility, the current price near the 52-week low and the implied earnings recovery (forward P/E of 21x) could be attractive. However, the recent decline in revenue and the stock's 40% underperformance versus the market over the past six months are major red flags. It could be a good buy only for those who believe the company's fundamentals will bottom and rebound in the next 12 months, and who are prepared to endure further downside if that thesis is wrong.
TECH is unsuitable for short-term trading due to its high volatility (beta 1.405), negative momentum, and lack of near-term catalysts. It does not pay a meaningful dividend (yield 0.62%). The investment thesis is fundamentally a turnaround story that requires several quarters to play out. Therefore, it is only appropriate for a long-term investor with a minimum horizon of 18-24 months, who can wait for evidence of a fundamental recovery. Even for long-term holders, the position size should be limited due to the high uncertainty and risk profile.
